MONARCH 1, a phase 2 study of abemaciclib, a CDK4 and CDK6 inhibitor, as a single agent, in patients with refractory HR+/HER2− metastatic breast cancer

PURPOSE: The phase 2 MONARCH 1 study was designed to evaluate the single-agent activity and adverse event (AE) profile of abemaciclib, a selective inhibitor of CDK4 and CDK6, in women with refractory hormone receptor positive (HR+), HER2− metastatic breast cancer (MBC). EXPERIMENTAL DESIGN: MONARCH...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Clin Cancer Res
Autori principali: Dickler, Maura N., Tolaney, Sara M., Rugo, Hope S., Cortés, Javier, Diéras, Véronique, Patt, Debra, Wildiers, Hans, Hudis, Clifford A., O’Shaughnessy, Joyce, Zamora, Esther, Yardley, Denise A., Frenzel, Martin, Koustenis, Andrew, Baselga, José
Natura: Artigo
Lingua:Inglês
Pubblicazione: 2017
Soggetti:
Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC5581697/
https://ncbi.nlm.nih.gov/pubmed/28533223
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-17-0754
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi